CoChat

Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection

Open access
Rappaport, Amy R., Hong, Sue-Jean, Scallan, Ciaran D., Gitlin, Leonid, Akoopie, Arvin, Boucher, Gregory R., Egorova, Milana, Espinosa, J. Aaron, Fidanza, Mario, Kachura, Melissa A., Shen, Annie, Sivko, Gloria, Van Abbema, Anne, Veres, Robert L., Jooss, Karin · 2022 · Nature Communications
Cited by 57

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic continues to spread globally, highlighting the urgent need for safe and effective vaccines that could be rapidly mobilized to immunize large populations. We report the preclinical development of a self-amplifying mRNA (SAM) vaccine encoding a prefusion stabilized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein and demonstrate strong cellular and humoral immune responses at low doses in mice and rhesus macaques. The homologous prime-boost vaccination regimen of SAM at 3, 10 and 30 μg induced potent neutralizing antibody (nAb) titers in rhesus macaques following two SAM vaccinations at all dose levels, with the 10 μg dose generating geometric mean titers (GMT) 48-fold greater than the GMT of a panel of SARS-CoV-2 convalescent human sera. Spike-specific T cell responses were observed with all tested vaccine regimens. SAM vaccination provided protective efficacy against SARS-CoV-2 challenge as both a homologous prime-boost and as a single boost following ChAd prime, demonstrating reduction of viral replication in both the upper and lower airways. The SAM vaccine is currently being evaluated in clinical trials as both a homologous prime-boost regimen at low doses and as a boost following heterologous prime.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-31005-z

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 14

  1. Millet, J. K. & Whittaker, G. R. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc. Natl Acad. Sci. USA 111, 15214–15219 (2014). · DOI · Paper page
  2. Lambe, T. et al. ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models. Commun. Biol. 4, 915 (2021). · DOI
  3. Wölfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465–469 (2020). · DOI · Paper page
  4. Chu, L. et al. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine 39, 2791–2799 (2021). · DOI · Paper page
  5. Bonifacius, A. et al. COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. Immunity 54, 340–354.e6 (2021). · DOI · Paper page
  6. Schmidt, T. et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat. Med. 27, 1530–1535 (2021). · DOI · Paper page
  7. Atmar, R. L. et al. HeterologousSARS-CoV-2 booster vaccinations: preliminary report. Preprint at medRxiv https://doi.org/10.1101/2021.10.10.21264827 (2021). · DOI
  8. Catenacci, D. V. et al. Clinical outcomes and immune responses in a phase I/II study of personalized, neoantigen-directed immunotherapy in patients with advanced MSS-CRC, GEA and NSCLC. Annal. Oncol. 32, S830–S831 (2021). · DOI
  9. Chin, J. X., Chung, B. K. & Lee, D. Y. Codon Optimization OnLine (COOL): a web-based multi-objective optimization platform for synthetic gene design. Bioinformatics 30, 2210–2212 (2014). · DOI · Paper page
  10. Scallan, C. D., Lindbloom, J. D. & Tucker, S. N. Oral modeling of an adenovirus-based quadrivalent influenza vaccine in ferrets and mice. Infect. Dis. Ther. 5, 165–183 (2016). · doi:10.1007/s40121-016-0108-z
  11. Geisbert, T. W. et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375, 1896–1905 (2010). · DOI · Paper page
  12. Moodie, Z. et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol. Immunother. 59, 1489–1501 (2010). · DOI · Paper page
  13. Hamilton, M. A., Russo, R. C. & Thurston, R. V. Trimmed Spearman-Karber method for estimating median lethal concentrations in toxicity bioassays. Environ. Sci. Technol. 11, 714–719 (1977). · DOI · Paper page
  14. Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro. Surveill. 25, 2000045 (2020). · DOI · Paper page

Cited by

See all 57

Metadata

Authors
Rappaport, A. R., Hong, S.-J., Scallan, C. D., Gitlin, L., Akoopie, A., Boucher, G. R., Egorova, M., Espinosa, J. A., Fidanza, M., Kachura, M. A., Shen, A., Sivko, G., Van Abbema, A., Veres, R. L., & Jooss, K.
Venue
Nature Communications
Published
2022-06-07
Volume
13
Issue
1
Pages
3289-3289
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4281709867
Cited by
57
References
27
FWCI
5.56
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • Bill and Melinda Gates Foundation
  • U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection. https://app.cochat.ai/papers/10.1038/s41467-022-31005-z
The paper
Rappaport, A. R., Hong, S.-J., Scallan, C. D., Gitlin, L., Akoopie, A., Boucher, G. R., Egorova, M., Espinosa, J. A., Fidanza, M., Kachura, M. A., Shen, A., Sivko, G., Van Abbema, A., Veres, R. L., & Jooss, K. (2022). Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection. Nature Communications. https://doi.org/10.1038/s41467-022-31005-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.